Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

ABSTRACT:

Background & aims

The safety profiles of boceprevir and telaprevir in the treatment of chronic hepatitis C, administered in academic and community centres across the United States, were evaluated.

Methods

In 90 medical centres, patients with chronic HCV received pegylated interferon, ribavirin, and either telaprevir or boceprevir per local standard of care. Demographic, adverse event, clinical, and virological data were collected during treatment and follow-up.

Results

A total of 2084 patients (97% HCV genotype 1) received at least one dose of a protease inhibitor. At baseline, 38% of patients had cirrhosis, and 57% had received at least one prior treatment for hepatitis C. Serious adverse events occurred in 12% of patients receiving protease inhibitor therapy. Overal

SUBMITTER: Gordon SC 

PROVIDER: S-EPMC4586075 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature